Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 1,865 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Small portion Clear all
Recruiting Not applicable Interventional

Biofield Therapy for the Support of Immunotherapy-related Symptoms Among Adult Cancer Patients - A Pilot Study

NCT07581080
View directory record Official record
Conditions
Cancer, Immunotherapy, Fatigue Related to Cancer Treatment, Pain, Stress
Interventions
Usui Reiki Intervention
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Irvine, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 28, 2026, 9:32 AM EDT
Active, not recruiting Not applicable Interventional

Development of an Intervention to Enhance Cancer Pain Management

NCT03752268
View directory record Official record
Conditions
Other Cancer
Interventions
Enhancing Cancer Pain Management
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 28, 2026, 9:32 AM EDT
Completed Not applicable Interventional Results available

Targeting Obesity to Optimize Health in Cardiac Rehab (TOPCARE)

NCT03423238
View directory record Official record
Conditions
Obesity, Weight Loss, CHD - Coronary Heart Disease
Interventions
Exercise, Health Education, Exercise Compliance, Calorie-Restricted Diet, Behavioral Modification, Weight-Loss Compliance, Dietary Counseling
Other · Behavioral · Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 28, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Results available

Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

NCT01606878
View directory record Official record
Conditions
Childhood Solid Neoplasm, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Neuroblastoma
Interventions
Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Questionnaire Administration, Topotecan Hydrochloride, Vincristine Sulfate
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
13 Months to 21 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 28, 2026, 9:32 AM EDT
Completed Phase 2 Interventional

Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

NCT02725489
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer, Cervical Cancer, Endometrial Cancer
Interventions
Vigil, Durvalumab
Biological · Drug
Lead sponsor
Mary Crowley Medical Research Center
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 28, 2026, 9:32 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors

NCT04440735
View directory record Official record
Conditions
Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
Interventions
DSP107, Atezolizumab
Biological
Lead sponsor
Kahr Medical
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
La Jolla, California • Aurora, Colorado • Lake Mary, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 28, 2026, 9:32 AM EDT
Completed Not applicable Interventional

Novel Strategies for Innovating Deceased Donor Procurement

NCT03007017
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Deceased donor nephrectomy, prior to cross clamp of donor aorta, Deceased donor nephrectomy, standard of care
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 28, 2026, 9:32 AM EDT
Withdrawn Phase 1 Interventional

Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma

NCT05228249
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Loncastuximab Tesirine, Melphalan
Procedure · Drug · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 28, 2026, 9:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

A 2-part Phase 1/2 Open-label Trial on ODM-212

NCT07563738
View directory record Official record
Conditions
Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
ODM-212, Ipilimumab and nivolumab, Gemcitabine and nab-paclitaxel, sotorasib
Drug
Lead sponsor
Orion Corporation, Orion Pharma
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Fort Worth, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 28, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Results available

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

NCT01999985
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer (NSCLC)
Interventions
Dasatinib - 1A, Afatinib - 1A, Dasatinib - 1B, Afatinib - 1B
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 28, 2026, 9:32 AM EDT
Recruiting Not applicable Interventional

PTSD Treatment for Veterans With Serious Mental Illness to Improve Functional Outcomes

NCT05674617
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic; Mental Disorders
Interventions
Written Exposure Therapy, PTSD Education
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 28, 2026, 9:32 AM EDT
Completed Phase 1 Interventional Results available

A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

NCT02573259
View directory record Official record
Conditions
Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA
Interventions
PF-06801591
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
24
States / cities
Los Angeles, California • Santa Monica, California • Louisville, Kentucky + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 28, 2026, 9:32 AM EDT
Terminated Phase 2 Interventional Results available

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

NCT06094296
View directory record Official record
Conditions
NSCLC
Interventions
BMS-986315, Nivolumab, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Glendale, California • Clermont, Florida • Orange City, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 28, 2026, 9:32 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Seizure Rescue Medication (RM) as Part of a Comprehensive Epilepsy Self-management Package of Care

NCT06346262
View directory record Official record
Conditions
Epilepsy
Interventions
SMART RM, Valtoco Nasal Product
Behavioral · Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 28, 2026, 9:32 AM EDT
Completed Not applicable Interventional

MyLife: A Digital Health Coaching Program

NCT03529903
View directory record Official record
Conditions
Lifestyle-related Condition, Obesity, Sedentary Lifestyle, PreDiabetes, Hypertension
Interventions
Health Coaching
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 28, 2026, 9:32 AM EDT
Not listed Not applicable Interventional

Stress and Fertility: How to Lower Stress When Trying to Conceive

NCT03031990
View directory record Official record
Conditions
Anxiety, Infertility, Female
Interventions
In-person yoga for fertility group, Online yoga for fertility group, In person discussion only group
Behavioral
Lead sponsor
Fertility Centers of Illinois
Other
Eligibility
24 Years to 42 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Oct 28, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

NCT00733746
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
erlotinib hydrochloride, gemcitabine hydrochloride, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
23
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 28, 2026, 9:32 AM EDT
Completed Not applicable Interventional

AB-Intra- and Post-Operative Measures of Auditory Function

NCT03685461
View directory record Official record
Conditions
Hearing Loss, Cochlear Implant
Interventions
Electrocochleography
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 28, 2026, 9:32 AM EDT
Completed Phase 2 Interventional Results available

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

NCT03128359
View directory record Official record
Conditions
Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Graft Versus Host Disease, Hodgkin Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Secondary Myelodysplastic Syndrome
Interventions
Busulfan, Cyclophosphamide, Fludarabine Phosphate, Hematopoietic Cell Transplantation, Laboratory Biomarker Analysis, Melphalan Hydrochloride, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Quality-of-Life Assessment, Tacrolimus, Total-Body Irradiation
Drug · Procedure · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
5 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 28, 2026, 9:32 AM EDT
Completed Not applicable Interventional Results available

Randomized Endo-Vein Graft Prospective

NCT01850082
View directory record Official record
Conditions
Coronary Artery Bypass Grafting
Interventions
Vein Harvesting Procedures
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
16
States / cities
Tucson, Arizona • San Francisco, California • Gainesville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 28, 2026, 9:32 AM EDT
Terminated Not applicable Interventional

Parent Understanding of Discharge Instructions

NCT04063241
View directory record Official record
Conditions
Parent-Child Relations
Interventions
Health Literacy-Informed Discharge Instructions, Provider Training
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
Not listed
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 28, 2026, 9:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Personalized, Augmented Cognitive Training (PACT) for Service Members and Veterans with a History of TBI

NCT04560946
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Personalized Augmented Cognitive Training (PACT), Enhanced Treatment As Usual
Behavioral
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
18 Years to 55 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 28, 2026, 9:32 AM EDT
Completed Not applicable Interventional

Effectiveness of Closed Loop Stimulation (CLS) With His Bundle Lead Placement

NCT03601754
View directory record Official record
Conditions
Sinus Node Dysfunction
Interventions
Treadmill/Bicycle exercise testing
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 28, 2026, 9:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Satiety of High-Protein Ramen Noodles

NCT05725681
View directory record Official record
Conditions
Appetitive Behavior
Interventions
High protein ramen, Standard ramen
Other
Lead sponsor
Texas Tech University
Other
Eligibility
25 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 28, 2026, 9:32 AM EDT